Effectiveness of Nirsevimab Immunoprophylaxis Against Respiratory Syncytial Virus-Related Outcomes in Hospital and Primary Care Settings: A Retrospective Cohort Study in Infants in Catalonia (Spain)

• 2024

  Sign in to bookmark this resource.

  Sign in
• Ermengol Coma; Montserrat Martinez-Marcos; Eduardo Hermosilla; Jacobo Mendioroz; Anna Reñé; Francesc Fina
PMID: 38857952DOI: https://dx.doi.org/10.1136/archdischild-2024-327153

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This study in Catalonia, Spain looks at the effectiveness of nirsevimab, a monoclonal antibody for RSV, in infants under 6 months old. The study shows significant reductions in hospital and ICU admissions for RSV-related conditions after nirsevimab administration. The research also shows fewer cases of RSV infections and related illnesses like pneumonia and bronchiolitis treated in primary care settings. These findings help guide public health decisions on using nirsevimab for preventing severe RSV outcomes in young children during their first epidemic season.

---

Tags

Focus Area: Infectious Disease

Audiences: Nurses; Physicians; Public Health Professionals

Emergency Management Stage: Preparedness (Prevention / Protection)

Collection: Nirsevimab Library

Keywords: Antiviral Agents; Bronchiolitis; Hospitalization; Infant; Infant, Newborn; Intensive Care Units; Respiratory Syncytial Virus Infections; Spain; Antibodies, Monoclonal, Humanized

Institutions: Institut Catala de la Salut; Generalitat de Catalunya; University of Barcelona

---

More like this

Assessment of Effectiveness and Impact of Universal Prophylaxis With Nirsevimab for Prevention of Hospitalizations Due to Respiratory Syncytial Virus in Infants. The NIRSE-GAL Study Protocol 2024 · Instituto de Investigación Sanitaria, World Health Organization (WHO), University of Santiago de Compostela, Instituto de Salud Carlos III Evaluation of Antibody-Based Preventive Alternatives for Respiratory Syncytial Virus: A Novel Multi-Criteria Decision Analysis Framework and Assessment of Nirsevimab in Spain 2024 · University Carlos III, BioMad, Fisabio-Public Health, Catholic University of Valencia, Instituto de Salud Carlos III, Weber Foundation Diarrheal Deaths After the Introduction of Rotavirus Vaccination in 4 Countries 2021 · Universidad de Cartagena, Centers for Disease Control and Prevention (CDC), Universidad de Santiago de Chile, Pan American Health Organization, Universidad Nacional de Colombia

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---